Van Parijs, H.; Cecilia-Joseph, E.; Gorobets, O.; Storme, G.; Adriaenssens, N.; Heyndrickx, B.; Verschraegen, C.; Nguyen, N.P.; De Ridder, M.; Vinh-Hung, V. Lung-Heart Toxicity in a Randomized Clinical Trial of Hypofractionated Image Guided Radiation Therapy for Breast Cancer. Frontiers in Oncology 2023, 13, doi:10.3389/fonc.2023.1211544.
Van Parijs, H.; Cecilia-Joseph, E.; Gorobets, O.; Storme, G.; Adriaenssens, N.; Heyndrickx, B.; Verschraegen, C.; Nguyen, N.P.; De Ridder, M.; Vinh-Hung, V. Lung-Heart Toxicity in a Randomized Clinical Trial of Hypofractionated Image Guided Radiation Therapy for Breast Cancer. Frontiers in Oncology 2023, 13, doi:10.3389/fonc.2023.1211544.
Van Parijs, H.; Cecilia-Joseph, E.; Gorobets, O.; Storme, G.; Adriaenssens, N.; Heyndrickx, B.; Verschraegen, C.; Nguyen, N.P.; De Ridder, M.; Vinh-Hung, V. Lung-Heart Toxicity in a Randomized Clinical Trial of Hypofractionated Image Guided Radiation Therapy for Breast Cancer. Frontiers in Oncology 2023, 13, doi:10.3389/fonc.2023.1211544.
Van Parijs, H.; Cecilia-Joseph, E.; Gorobets, O.; Storme, G.; Adriaenssens, N.; Heyndrickx, B.; Verschraegen, C.; Nguyen, N.P.; De Ridder, M.; Vinh-Hung, V. Lung-Heart Toxicity in a Randomized Clinical Trial of Hypofractionated Image Guided Radiation Therapy for Breast Cancer. Frontiers in Oncology 2023, 13, doi:10.3389/fonc.2023.1211544.
Abstract
TomoBreast hypothesized that hypofractionated 15 fractions/3 weeks image-guided radiation therapy (H-IGRT) can reduce lung-heart toxicity, as compared with normofractionated 25-33 fractions/5-7 weeks conventional radiation therapy (CRT). 123 women with stage I-II operated breast cancer were randomized to receive CRT (N=64) or H-IGRT (N=59). The primary endpoint used a four-items measure of the time to 10% alteration in any of patient self-reported measure, physician clinical evaluation, echocardiography or lung function tests, analyzed by intention-to-treat without exclusion. Results found comparable survivals, but H-IGRT significantly reduced the toxicity measured by lung diffusion capacity and alveolar volume as compared with CRT, G1 in 53% (31/59) versus 72% (44/61) patients, P=0.006; G2, 29% versus 48%, P=0.020. H-IGRT significantly reduced the risk of composite cardio-pulmonary alteration at 5 years, 10.2% versus 26.7%, P=0.024. In conclusion, TomoBreast is a proof-of-concept that image-guided radiation-therapy can improve the overall balance of lung-heart outcomes in breast cancer adjuvant therapy. Furthermore, the significance of the findings supports the efficacy of a small trial size design, which can be critical when clinical research resources are limited.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.